PMID- 23531118
OWN - NLM
STAT- MEDLINE
DCOM- 20140519
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Linking)
VI  - 15
IP  - 10
DP  - 2013 Oct
TI  - Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus 
      patients with mild hyperglycaemia: a prospective, double-blind, randomized, 
      1-year study.
PG  - 906-14
LID - 10.1111/dom.12102 [doi]
AB  - AIM: To prospectively evaluate the efficacy and safety of alogliptin versus 
      glipizide in elderly patients with type 2 diabetes mellitus (T2DM) over 1 year of 
      treatment. METHODS: This was a randomized, double-blind, active-controlled study 
      of elderly T2DM patients (aged 65-90 years) with mild hyperglycaemia on 
      diet/exercise therapy alone [glycosylated haemoglobin (HbA1c) 6.5-9.0%] or plus 
      oral antidiabetic monotherapy (HbA1c 6.5-8.0%). Patients were randomized to 
      once-daily alogliptin 25 mg or glipizide 5 mg titrated to 10 mg, if needed. 
      Hypoglycaemic episodes were systematically captured under predefined criteria. 
      RESULTS: In the primary analysis, HbA1c mean changes from a baseline of 7.5% were 
      -0.14% with alogliptin (n = 222) and -0.09% with glipizide (n = 219) at the end 
      of the study, demonstrating non-inferiority of alogliptin to glipizide [least 
      squares (LS) mean difference = -0.05%; one-sided 97.5% confidence interval (CI): 
      -infinity, 0.13%]. More clinically relevant HbA1c reductions occurred among patients who 
      completed the study: -0.42 and -0.33% with alogliptin and glipizide, with 
      non-inferiority again confirmed (LS mean difference = -0.09%; one-sided 97.5% CI: 
      -infinity, 0.07%). Overall, alogliptin was safe and well tolerated, with notably fewer 
      hypoglycaemic episodes than glipizide [5.4% (31 episodes) vs. 26.0% (232 
      episodes), respectively]; three patients experienced severe hypoglycaemia, all 
      with glipizide. Alogliptin also resulted in favourable weight changes versus 
      glipizide (-0.62 vs. 0.60 kg at week 52; p < 0.001). CONCLUSIONS: Alogliptin 
      monotherapy maintained glycaemic control comparable to that of glipizide in 
      elderly patients with T2DM over 1 year of treatment, with substantially lower 
      risk of hypoglycaemia and without weight gain.
CI  - (c) 2013 John Wiley & Sons Ltd.
FAU - Rosenstock, J
AU  - Rosenstock J
AD  - Dallas Diabetes and Endocrine Center at Medical City, Dallas, TX, USA.
FAU - Wilson, C
AU  - Wilson C
FAU - Fleck, P
AU  - Fleck P
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20130418
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Piperidines)
RN  - 0 (Triglycerides)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 56HH86ZVCT (Uracil)
RN  - 9100L32L2N (Metformin)
RN  - JHC049LO86 (alogliptin)
RN  - X7WDT95N5C (Glipizide)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Blood Glucose/drug effects
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/mortality
MH  - Dipeptidyl-Peptidase IV Inhibitors/adverse effects/*therapeutic use
MH  - Dizziness/chemically induced
MH  - Double-Blind Method
MH  - Female
MH  - Glipizide/adverse effects/*therapeutic use
MH  - Glycated Hemoglobin/drug effects
MH  - Headache/chemically induced
MH  - Humans
MH  - Hyperglycemia/blood/*drug therapy
MH  - Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Metformin/therapeutic use
MH  - Piperidines/adverse effects/*therapeutic use
MH  - Prospective Studies
MH  - Treatment Outcome
MH  - Triglycerides/blood
MH  - Uracil/adverse effects/*analogs & derivatives/therapeutic use
MH  - Weight Gain/drug effects
OTO - NOTNLM
OT  - alogliptin
OT  - dipeptidyl peptidase-4 inhibitor
OT  - elderly
OT  - glipizide
OT  - hypoglycaemia
OT  - older
OT  - prospective
OT  - type 2 diabetes mellitus
EDAT- 2013/03/28 06:00
MHDA- 2014/05/20 06:00
CRDT- 2013/03/28 06:00
PHST- 2012/10/10 00:00 [received]
PHST- 2012/11/20 00:00 [revised]
PHST- 2013/02/22 00:00 [accepted]
PHST- 2013/03/28 06:00 [entrez]
PHST- 2013/03/28 06:00 [pubmed]
PHST- 2014/05/20 06:00 [medline]
AID - 10.1111/dom.12102 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2013 Oct;15(10):906-14. doi: 10.1111/dom.12102. Epub 2013 
      Apr 18.